DOI: 10.5061/dryad.6t1g1jxbs
title: Impact of an integrated intervention package during preconception, pregnancy, and early childhood on inflammation, IGF-1, IGFBP3 during the first 6 months of life: Findings from the WINGS randomized controlled trial

description: Early-life interventions targeting maternal and child health, nutrition,
 and psychosocial care may influence infant growth and immune development
 by modulating systemic inflammation and growth factor pathways. However,
 causal evidence of comprehensive, integrated interventions initiated
 during early life is limited. The study was nested in a factorial
 randomized controlled trial (RCT) in women aged 18–30 years. Participants
 included in this study were randomized to receive either a preconception
 intervention package or routine care until early childhood.  The
 intervention included health care for growth-related conditions,
 nutrition, WASH (water, sanitation, and hygiene), and psychosocial care.
 The primary study demonstrated a substantial effect of the intervention on
 growth and development. Blood samples from 381 (178 from the intervention
 group and 203 from the control group) infants were analyzed at 3 and 6
 months of age for inflammatory and growth-related biomarkers: C-reactive
 protein (CRP), alpha-1-acid glycoprotein (AGP), insulin-like growth factor
 1 (IGF-1), and IGF binding protein 3 (IGFBP3). Generalized linear models
 were used to estimate the mean differences and relative risks of
 inflammatory markers and growth-related biomarkers between the
 intervention and routine care groups. Baseline maternal
 characteristics were similar between the two study groups. At 3 and 6
 months, the proportion of infants with CRP levels greater than 5 mg/L was
 similar in both groups. No significant differences were observed in AGP or
 IGF-1 concentrations at either time point. IGFBP3 was lower in the
 intervention group at 3 months (adjusted mean difference: –30.8 ng/mL; 95%
 CI: –55.3, –6.3), but this effect was not sustained at 6 months. An
 integrated intervention delivered from preconception through pregnancy and
 early childhood did not result in reductions in markers of systemic
 inflammation or sustained improvements in growth factor profiles during
 the first six months of life. These findings highlight the complexity of
 early-life inflammatory processes and underscore the need for further
 research on the long-term and synergistic effects of early interventions
 in low-resource settings.
description: # Impact of an integrated intervention package during preconception,
 pregnancy, and early childhood on inflammation, IGF-1, IGFBP3 during the
 first 6 months of life: Findings from the WINGS randomized controlled
 trial Dataset DOI:
 [10.5061/dryad.6t1g1jxbs](https://doi.org/10.5061/dryad.6t1g1jxbs) ##
 Description of the data and file structure
 File: dataset_inflammatorymarkermanuscript_28.11.25.xlsx Integrated
 Intervention Effects on Infant Inflammation and IGF Axis The dataset
 originated from a randomized controlled trial. The study involved
 recruitment, interventions, and follow-up assessments. Blood samples were
 collected by the research team. All outcome assessments were conducted by
 a separate team that was not involved in the intervention delivery and was
 blinded to group assignments before the measurement process. Ethical
 clearance for this study was granted by the Ethics Review Committee of the
 Society for Applied Studies, New Delhi, India. This study was registered
 with the Clinical Trial Registry of India. ### Files and variables ####
 File: dataset_inflammatorymarkermanuscript_05.10.25.xlsx **Description:** 
 ##### Variables | group\_ad | 0 = Control | | :-------------------- |
 :--------------------------------------------------------- | | 
 
 | 1 = Intervention | | 
 
 | 
 
 | | woman\_age | continuous variable | | 
 
 | 
 
 | | woman\_height | continuous variable | | 
 
 | 
 
 | | bmi\_cat\_markerstudy | 1 = less than 18.5 | | 
 
 | 2 = 18.5 to 24.99 | | 
 
 | 3 = more than equal to 25 | | 
 
 | 
 
 | | fam\_typ\_markerstudy | 1 = nuclear family | | 
 
 | 4 = Joint/ Extended family | | 
 
 | 
 
 | | school\_cat | 1 = &gt;=12 years | | 
 
 | 2 = &lt;12 years | | 
 
 | 
 
 | | homemaker | 1 = homemaker | | 
 
 | 0 = not- homemaker | | 
 
 | 
 
 | | bplcard1 | 1 = do not possess bpl card | | 
 
 | 2 = possess bpl card | | 
 
 | 
 
 | | insurance | 1 = Family covered by health insurance scheme | | 
 
 | 
 
 | | birth\_place | 1 = Middle level hospital/ small hospital/ birthing
 centre | | 
 
 | 2 = Large hospital | | 
 
 | 3 = Home | | 
 
 | 
 
 | | crp\_3m\_cat | 1 = &gt; 5 mg/L | | 
 
 | 0 = &lt;= 5 mg/L | | 
 
 | 
 
 | | crp\_6m\_cat | 1 = &gt; 5 mg/L | | 
 
 | 0 = &lt;= 5 mg/L | | 
 
 | 
 
 | | agp\_3m\_cat | 1 = &gt; 1 g/L | | 
 
 | 0 = &lt;= 1 g/L | | 
 
 | 
 
 | | agp\_6m\_cat | 1 = &gt; 1 g/L | | 
 
 | 0 = &lt;= 1 g/L | | 
 
 | 
 
 | | crpmgl\_3m\_upd | CRP at 3 months (mg/L) | | 
 
 | 
 
 | | crpmgl\_6m\_upd | CRP at 6 months (mg/L) | | 
 
 | 
 
 | | agpgl\_3m\_upd | AGP at 3 months (g/L) | | 
 
 | 
 
 | | agpgl\_6m\_upd | AGP at 6 months (g/L) | | 
 
 | 
 
 | | igf1ngml\_3m\_upd | IGF-1 at 3 months (ng/mL) | | 
 
 | 
 
 | | igf1ngml\_6m\_upd | IGF-1 at 6 months (ng/mL) | | 
 
 | 
 
 | | igfbp3ngml\_3m | IGFBP3 at 3 months (ng/mL) | | 
 
 | 
 
 | | igfbp3ngml\_6m | IGFBP3 at 6 months (ng/mL) | | n/a | not available |
 ## Code/software 1. Google sheet OR 2. Microsoft Excel 2007 or later ##
 Access information Other publicly accessible locations of the data: * None
 Data was derived from the following sources: * Community-based randomised
 controlled study. ## Human subjects data I confirm that I received
 informed consent from the participants to publish the de-identified data
 in the public domain, and I have removed all the personal identifiers from
 the data.